Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial.

[1]  A. Coutinho,et al.  Fetal-onset IPEX: report of two families and review of literature. , 2015, Clinical immunology.

[2]  M. Lenardo,et al.  Novel diagnostic and therapeutic approaches for autoimmune diabetes--a prime time to treat insulitis as a disease. , 2015, Clinical immunology.

[3]  A. Marwaha,et al.  Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes. , 2014, Clinical immunology.

[4]  M. V. von Herrath,et al.  Regulatory T cells control diabetes without compromising acute anti-viral defense. , 2014, Clinical immunology.

[5]  W. Młynarski,et al.  Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. , 2014, Clinical immunology.

[6]  C. Mathieu,et al.  Dietary Supplementation With High Doses of Regular Vitamin D3 Safely Reduces Diabetes Incidence in NOD Mice When Given Early and Long Term , 2014, Diabetes.

[7]  T. Pieber,et al.  High-dose cholecalciferol supplementation significantly increases peripheral CD4+ Tregs in healthy adults without negatively affecting the frequency of other immune cells , 2014, European Journal of Nutrition.

[8]  T. Pieber,et al.  Vitamin D and Immune Function , 2013, Nutrients.

[9]  M. Gershwin,et al.  The Implication of Vitamin D and Autoimmunity: a Comprehensive Review , 2013, Clinical Reviews in Allergy & Immunology.

[10]  K. Raza,et al.  Availability of 25-Hydroxyvitamin D3 to APCs Controls the Balance between Regulatory and Inflammatory T Cell Responses , 2012, The Journal of Immunology.

[11]  J. Bluestone,et al.  Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function , 2012, Diabetes.

[12]  S. Dib,et al.  Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus. , 2012, Archives of pediatrics & adolescent medicine.

[13]  W. Młynarski,et al.  Administration of CD4+CD25highCD127− Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children , 2012, Diabetes Care.

[14]  K. Herold,et al.  New and future immunomodulatory therapy in type 1 diabetes. , 2012, Trends in molecular medicine.

[15]  A. Neunkirchner,et al.  Naturally occurring regulatory T cells: markers, mechanisms, and manipulation , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  C. Daniel,et al.  Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer , 2012, Nature Reviews Drug Discovery.

[17]  C. Mathieu,et al.  Vitamin D and diabetes: Its importance for beta cell and immune function , 2011, Molecular and Cellular Endocrinology.

[18]  S. Quataert,et al.  Uncoupling of Proliferation and Cytokines From Suppression Within the CD4+CD25+Foxp3+ T–Cell Compartment in the 1st Year of Human Type 1 Diabetes , 2011, Diabetes.

[19]  JoAnn E. Manson,et al.  The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know , 2010, The Journal of clinical endocrinology and metabolism.

[20]  J. Buckner.  Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases , 2010, Nature Reviews Immunology.

[21]  Q. Ouyang,et al.  Cutting Edge: Increased IL-17–Secreting T Cells in Children with New-Onset Type 1 Diabetes , 2010, The Journal of Immunology.

[22]  G. Ghirlanda,et al.  No Protective Effect of Calcitriol on β-Cell Function in Recent-Onset Type 1 Diabetes , 2010, Diabetes Care.

[23]  P. Menheere,et al.  Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  E. Bonifacio,et al.  No Effect of the 1α,25-Dihydroxyvitamin D3 on β-Cell Residual Function and Insulin Requirement in Adults With New-Onset Type 1 Diabetes , 2010, Diabetes Care.

[25]  T. Pieber,et al.  Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? , 2010, The Israel Medical Association journal : IMAJ.

[26]  M. Mura,et al.  1,25-Dihydroxyvitamin D3 and IL-2 Combine to Inhibit T Cell Production of Inflammatory Cytokines and Promote Development of Regulatory T Cells Expressing CTLA-4 and FoxP31 , 2009, The Journal of Immunology.

[27]  K. Cerosaletti,et al.  Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects , 2009, Diabetes.

[28]  Xiang Yan,et al.  Protective effects of 1‐α‐hydroxyvitamin D3 on residual β‐cell function in patients with adult‐onset latent autoimmune diabetes (LADA) , 2009, Diabetes/metabolism research and reviews.

[29]  G. Szot,et al.  Expansion of Human Regulatory T-Cells From Patients With Type 1 Diabetes , 2009, Diabetes.

[30]  M. Peakman,et al.  Increased resistance to CD4+CD25hi regulatory T cell‐mediated suppression in patients with type 1 diabetes , 2008, Clinical and experimental immunology.

[31]  J. Buckner,et al.  The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells1 , 2008, The Journal of Immunology.

[32]  E. Bonifacio,et al.  Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4+CD25+FOXP3+ Regulatory T-Cells , 2008, Diabetes.

[33]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[34]  Soumitra Ghosh,et al.  Dynamic changes in CD4+ CD25+ high T cell apoptosis after the diagnosis of type 1 diabetes , 2007, Clinical and experimental immunology.

[35]  P. Lipsky,et al.  Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B Cell Differentiation , 2007, The Journal of Immunology.

[36]  Hans D. Ochs,et al.  IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity , 2007, Immunologic research.

[37]  M. Atkinson,et al.  No Alterations in the Frequency of FOXP3+ Regulatory T-Cells in Type 1 Diabetes , 2007, Diabetes.

[38]  W. Hagopian,et al.  At-Risk and Recent-Onset Type 1 Diabetic Subjects Have Increased Apoptosis in the CD4+CD25+high T-Cell Fraction , 2007, PloS one.

[39]  C. Mathieu,et al.  1Alpha,25-dihydroxyvitamin D3 restores thymocyte apoptosis sensitivity in non-obese diabetic (NOD) mice through dendritic cells. , 2005, Journal of autoimmunity.

[40]  M. Atkinson,et al.  Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. , 2005, Diabetes.

[41]  P. Gottlieb,et al.  CD4+CD25high regulatory T cells in human autoimmune diabetes. , 2005, Journal of autoimmunity.

[42]  M. Peakman,et al.  Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. , 2005, Diabetes.

[43]  C. Mathieu,et al.  1alpha,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. , 2004, Journal of autoimmunity.

[44]  L. Chatenoud,et al.  Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Flavell,et al.  CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-β–TGF-β receptor interactions in type 1 diabetes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Uskoković,et al.  A 1α,25-Dihydroxyvitamin D3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice , 2002 .

[47]  Svetlana Ten,et al.  Multiple immuno-regulatory defects in type-1 diabetes. , 2002, The Journal of clinical investigation.